Cardiovascular Systems Revenue 2006-2018 | CSII

Cardiovascular Systems revenue from 2006 to 2018. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Cardiovascular Systems Annual Revenue
(Millions of US $)
2018 $217
2017 $205
2016 $178
2015 $182
2014 $137
2013 $104
2012 $82
2011 $79
2010 $65
2009 $56
2008 $0
2008 $22
2007 $59
2007 $0
2006 $16
2006 $0
2005 $0
2005 $0
Cardiovascular Systems Quarterly Revenue
(Millions of US $)
Q2 2018 $60
Q1 2018 $56
Q4 2018 $59
Q3 2018 $56
Q2 2017 $53
Q1 2017 $50
Q4 2017 $53
Q3 2017 $52
Q2 2016 $50
Q1 2016 $50
Q4 2016 $48
Q3 2016 $44
Q2 2015 $41
Q1 2015 $44
Q4 2015 $48
Q3 2015 $47
Q2 2014 $45
Q1 2014 $41
Q4 2014 $40
Q3 2014 $35
Q2 2013 $32
Q1 2013 $30
Q4 2013 $29
Q3 2013 $26
Q2 2012 $25
Q1 2012 $23
Q4 2012 $23
Q3 2012 $21
Q2 2011 $20
Q1 2011 $19
Q4 2011 $22
Q3 2011 $20
Q2 2010 $19
Q1 2010 $18
Q4 2010 $18
Q3 2010 $17
Q2 2009 $15
Q1 2009 $15
Q4 2009 $16
Q3 2009 $15
Q2 2008 $0
Q1 2008 $12
Q4 2008 $0
Q3 2008 $8
Q2 2007 $0
Q1 2007 $0
Q4 2007 $56
Q3 2007 $3
Q2 2006 $0
Q1 2006 $4
Q4 2006 $4
Q3 2006 $3
Q2 2005 $0
Q1 2005 $0
Q4 2005 $0
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $1.377B $0.217B
Cardiovascular Systems, Inc., formerly known as Replidyne Inc., is headquartered in Saint Paul, Minnesota. It is a medical device company focusing on developing and commercializing interventional treatment systems for vascular disease. Its initial product, the Diamondback 360? Orbital Atherectomy System, is a minimally invasive catheter system for the treatment of peripheral arterial disease; and a range of plaque types, including calcified vessel lesions. The Diamondback 360? removes soft and calcified plaque in plaque-lined vessels through the orbital rotation of a diamond grit coated offset crown. The company refined its `orbital` technology to address the growing market need of providing a safer more effective atherectomy device.
Stock Name Country Market Cap PE Ratio
Abbott Laboratories (ABT) United States $140.412B 27.76
Medtronic (MDT) Ireland $123.010B 17.98
Stryker (SYK) United States $73.467B 26.97
Boston Scientific (BSX) United States $52.473B 25.58
Baxter (BAX) United States $39.558B 25.31
Zimmer Biomet Holdings (ZBH) United States $26.051B 16.68
Smith & Nephew SNATS (SNN) United Kingdom $17.542B 0.00
Canopy Growth (CGC) Canada $15.685B 0.00
ResMed (RMD) United States $14.159B 26.85
Aurora Cannabis (ACB) Canada $9.930B 70.07
Bio-Rad Laboratories (BIO) United States $9.309B 53.12
Hill-Rom Holdings (HRC) United States $6.934B 21.44
Perrigo (PRGO) Ireland $6.569B 10.65
Insulet (PODD) United States $5.896B 1989.40
GW Pharmaceuticals (GWPH) United Kingdom $5.140B 0.00
ICU Medical (ICUI) United States $4.857B 30.24
Haemonetics (HAE) United States $4.425B 39.25
Hutchison China MediTech (HCM) China $3.913B 0.00
Agios Pharmaceuticals (AGIO) United States $3.752B 0.00
Neogen (NEOG) United States $3.328B 51.11
NuVasive (NUVA) United States $2.858B 24.93
Quidel (QDEL) United States $2.654B 23.95
Aphria (APHA) $2.533B 112.44
National Vision Holdings (EYE) United States $2.263B 44.51
HEXO (HEXO) $1.414B 0.00
VAREX IMAGING (VREX) United States $1.295B 25.34
Phibro Animal Health (PAHC) United States $1.292B 18.57
AtriCure (ATRC) United States $1.089B 0.00
MacroGenics (MGNX) United States $0.939B 0.00
Lantheus Holdings (LNTH) United States $0.930B 25.13
Cerus (CERS) United States $0.874B 0.00
Omeros (OMER) United States $0.861B 0.00
PetIQ (PETQ) United States $0.843B 24.12
NanoString Technologies (NSTG) United States $0.751B 0.00
Meridian Bioscience (VIVO) United States $0.722B 21.52
OraSure Technologies (OSUR) United States $0.705B 30.89
Evolus (EOLS) United States $0.685B 0.00
Eagle Pharmaceuticals (EGRX) United States $0.667B 22.70
TG Therapeutics (TGTX) United States $0.655B 0.00
LeMaitre Vascular (LMAT) United States $0.609B 28.99
Surmodics (SRDX) United States $0.603B 87.71
Quanterix (QTRX) United States $0.545B 0.00
BioLife Solutions (BLFS) United States $0.376B 154.92
Rockwell Medical (RMTI) United States $0.367B 0.00
Insys Therapeutics (INSY) United States $0.352B 0.00
Vapotherm (VAPO) United States $0.330B 0.00
Utah Medical Products (UTMD) United States $0.315B 20.48
Owens & Minor (OMI) United States $0.284B 3.94
Bovie Medical (APYX) United States $0.266B 0.00
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.265B 0.00
Cytosorbents (CTSO) United States $0.260B 0.00
Zynex (ZYXI) United States $0.144B 15.37
Fonar (FONR) United States $0.142B 7.59
Surface Oncology (SURF) United States $0.126B 0.00
Chimerix (CMRX) United States $0.102B 0.00
Chembio Diagnostics (CEMI) United States $0.099B 0.00
Female Health (VERU) United States $0.095B 0.00
United-Guardian (UG) United States $0.088B 18.43
Conatus Pharmaceuticals (CNAT) United States $0.087B 0.00
InfuSystems Holdings (INFU) United States $0.086B 0.00
CAS Medical Systems (CASM) United States $0.071B 0.00
Trinity Biotech (TRIB) Ireland $0.070B 20.71
Oramed Pharmaceuticals (ORMP) United States $0.057B 0.00
Neurotrope (NTRP) United States $0.055B 0.00
ImmuCell (ICCC) United States $0.038B 0.00
Valeritas Holdings (VLRX) United States $0.037B 0.00
Senestech (SNES) United States $0.027B 0.00
Myomo (MYO) United States $0.021B 0.00
Capricor Therapeutics (CAPR) United States $0.017B 0.00
InVivo Therapeutics Holdings (NVIV) United States $0.016B 0.00
Akers Biosciences Inc (AKER) United States $0.014B 0.00
Cellectar Biosciences (CLRB) United States $0.012B 0.00
NeuroMetrix (NURO) United States $0.009B 16.00